Collectively, these results robustly support the synergistic anti-tumoral effects of YJ1206 and AKT inhibitors, both in vitro and in vivo, underscoring their potential as a combined therapeutic strategy for advanced prostate cancer management. The gene discussed is AKT1; the disease is prostate carcinoma.